Mitotic homologous recombination (HR) is critical for the repair of double-strand breaks, and conditions that stimulate HR are associated with an increased risk of deleterious sequence rearrangements that can promote cancer. Because of the difficulty of assessing HR in mammals, little is known about HR activity in mammalian tissues or about the effects of cancer risk factors on HR in vivo. To study HR in vivo, we have used fluorescent yellow direct repeat mice, in which an HR event at a transgene yields a fluorescent phenotype. Results show that HR is an active pathway in the pancreas throughout life, that HR is induced in vivo by exposure to a cancer chemotherapeutic agent, and that recombinant cells accumulate with age in pancreatic tissue. Furthermore, we developed an in situ imaging approach that reveals an increase in both the frequency and the sizes of isolated recombinant cell clusters with age, indicating that both de novo recombination events and clonal expansion contribute to the accumulation of recombinant cells with age. This work demonstrates that aging and exposure to a cancer chemotherapeutic agent increase the frequency of recombinant cells in the pancreas, and it also provides a rapid method for revealing additional factors that modulate HR and clonal expansion in vivo.aging ͉ homologous recombination ͉ mutation ͉ chemotherapy C ells are constantly exposed to endogenous and exogenous DNA-damaging agents that can lead to double-strand breaks, either by causing breaks in both strands of DNA or by causing replication fork breakdown (1). Homologous recombination (HR) is critical for repairing double-strand breaks in mammalian cells. By using homologous DNA sequences present on the sister chromatid or homologous chromosome, damage can be repaired accurately without loss of sequence information (2, 3). Thus, the frequency of HR reflects both the levels of double-strand breaks and the ability of cells to use HR during DNA repair.Although HR is generally error-free, recombination between misaligned sequences can cause insertions, deletions, and translocations. Furthermore, recombination between homologous chromosomes can lead to loss of heterozygosity (4), and HR has been estimated to be the underlying cause of loss of heterozygosity 25-80% of the time in mammalian cells (e.g., see ref. 5). Germ-line mutations in genes that modulate the frequency of HR are associated with an increased risk of cancer. For example, inherited mutations in the HR helicases BLM and WRN lead to increased rates of HR (6, 7) and increase the risk of cancer (8).Whereas too much HR can be problematic, too little HR can also destabilize the genome, possibly as a result of nonhomologous end-joining of DNA ends created at broken replication forks (4, 9). In the pancreas, inherited mutations in BRCA1 (8), BRCA2 (10), and FANCC (11) increase the risk of pancreatic cancer, and loss of function of these genes suppresses HR (12-14), causing an increased frequency of tumorigenic sequence rearrangements (15,16). Although these findings sug...